Poor targeting of therapeutics leading to severe adverse effects on normal tissues is
considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug …

Ovarian cancer response to immunotherapy is limited; however, the evaluation of
sensitive/resistant target treatment subpopulations based on stratification by tumor …

One of the challenges in cancer chemotherapy is the low target to non-target ratio of
therapeutic agents which incur severe adverse effect on the healthy tissues. In this regard …

Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Targeted delivery combined with controlled drug release has a pivotal role in the future of
personalized medicine. This review covers the principles, advantages, and drawbacks of …

Although therapeutic targets have been developed for colorectal cancer (CRC) therapy, the
therapeutic effects are not ideal and the survival rate for CRC patients remains poor …

Microtubule-targeting agents (MTAs) constitute a diverse group of chemical compounds that
bind to microtubules and affect their properties and function. Disruption of microtubules …

The importance of early cancer diagnosis and improved cancer therapy has been clear for
years and has initiated worldwide research towards new possibilities in the care strategy of …

Targeted drug delivery in cancer typically focuses on maximising the endocytosis of drugs
into the diseased cells. However, there has been less focus on exploiting the differences in …